GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (tesaglitazar) in Subjects with Type 2 Diabetes

Exclusion Criteria

• - Type 1 diabetes
• - New York Heart Association heart failure Class III or IV
• - Treatment with chronic insulin
• - History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists.
• - History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
• - Creatinine levels above 1.2 mg/dL
• - Received any investigational product in other clinical studies within 30 days
• - Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient’s safety or successful participation in the clinical study